Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Discovery

Biomia

1 Drug Candidate

Biomia is a Copenhagen-based synthetic biology company developing novel plant-inspired drug candidates for unmet medical needs in pain, addiction, and depression. Using a proprietary AI-assisted drug discovery engine and fermentation-based biomanufacturing platform, the company engineers Monoterpene Indole Alkaloid (MIA) derivatives — a large family of plant-derived bioactive compounds including ibogaine analogs — with optimised halogenation to improve ADME properties and therapeutic profiles.

Drug Pipeline

1

MIA Drug Candidates (Ibogaine Analogue Program)

Discovery
Opioid Use Disorder (OUD)Depressive Disorders

AI-guided discovery of halogenated MIA (Monoterpene Indole Alkaloid) derivatives with ibogaine-like neuroplastogenic properties. Biosynthetic manufacturing platform enables efficient compound diversification.

Quick Facts

Type
Private Biotech
Founded
2022
Lead Stage
Discovery
Website
Visit